More recently, studies have shown that the combination of an FLT3 inhibitor (AC220) with OXPHOS inhibitors or glutaminase inhibitors was effective in models of FLT3 mutant AML [112,113]. This evidence concerns the gene FLT3 and acute myeloid leukemia.